[12] Patent
[11] Patent No.:GC0009244  
[45] Date of Publishing the Grant of the Patent: 31/Dec /2018                56/2018  
Number of the Decision to Grant the Patent:2018/140699
Date of the Decision to Grant the Patent:02/Dec/2018

[21] Application No.:GC 2010-16133

[22] Filing Date:22/6/2010

[30] Priority:

[33] State [32] Priority date [31] Priority No.
JP
JP
JP
26/6/2009
26/6/2009
26/6/2009
2009-151727
2009-151728
2009-151729

[72] Inventors:1- Hideyuki ITOUĜŒ2- Koji NAKAMICHIĜŒ3- Takashi TOSAKA

[73] Owner: Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil , Switzerland

[74] Agent: Saba & Co. T.M.P

  

 

  

[51]IPC:
Int. Cl.7: [A61K31/4965; C07D241/20; A61P11/06; A61P11/08; A61P13/12; A61P17/02; A61P25/00; A61P3/06; A61P37/00; A61P37/02; A61P43/00; A61P7/00; A61P7/02; A61P9/08; A61P9/10; A61P9/12]

[56] Cited Documents:

-EP 1400518 Al ( Nippon Shinyaku Co., Ltd.) 24 March 2004  
Examiner: PH. Sultana K. AlOudah

[54] CRYSTAL FORM OF COMPOUND 2-{4-[N-5,6-DIPHENYLPYRAZIN-2-YL-N-ISOPROPYLAMINO]BUTYLOXY}-N-METHYLSULFONYLACETAMIDE
[57] Abstract: [Problem] A main object of the present invention is to provide a novel crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide (hereinafter referred to as compound A).[Means for Resolution] A form-I crystal of compound A, showing diffraction peaks at 9.4 degrees, 9.8 degrees, 17.2 degrees and 19.4 degrees in the powder X-ray diffraction spectrum thereof. A form-II crystal of compound A, showing diffraction peaks at 9.0 degrees, 12.9 degrees, 20.7 degrees and 22.6 degrees in the powder X-ray diffraction spectrum thereof. A form-III crystal of compound A, showing diffraction peaks at 9.3 degrees, 9.7 degrees, 16.8 degrees, 20.6 degrees and 23.5 degrees in the powder X-ray diffraction spectrum thereof.[Selected Drawing] None.
No. of claims: 7     No. of figures: 6


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.